Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.47 |
| ▸ | TP53 | P04637 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 7/20 | 0.38 |
| ▸ | RAB9A | P51151 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3541679 | 0.95 | MAPT (0.48) | MAPTTP53POLBLMNAHTT | |
| Formic Acid SCHEMBL3537417 | 0.90 | LMNA (0.42) | MAPTTP53POLBLMNAHTT | |
| Formic Acid SCHEMBL3534517 | 0.87 | ROCK2 (0.42) | MAPTTP53POLBLMNAHTT | |
| SCHEMBL13314851 | 0.84 | LMNA (0.46) | MAPTTP53POLBLMNAHTT | |
| SCHEMBL3536144 | 0.84 | MAPT (0.46) | MAPTTP53POLBLMNAHTT | |
| SCHEMBL13314834 | 0.84 | MAPT (0.46) | MAPTTP53POLBLMNAHTT | |
| SCHEMBL3534984 | 0.84 | LMNA (0.46) | MAPTTP53POLBLMNAHTT | |
| SCHEMBL13314768 | 0.83 | MAPT (0.61) | MAPTTP53POLBLMNAHTT | |
| SCHEMBL3536226 | 0.83 | MAPT (0.61) | MAPTTP53POLBLMNAHTT | |
| Formic Acid SCHEMBL3533664 | 0.83 | MAPT (0.45) | MAPTTP53LMNATSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727979-B2 | Guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-01 | — | — | US | disclosed |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | NPFFR1, OGFR, NPFFR2 | MAPT 1891/4885TP53 3679/4885POLB 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.